BioPharm Insight Exclusive Event

Date: 9 January 2017 5:30 pm, Location: Chandran Art Gallery, 459 Geary Street, San Francisco, CA

Panelists:


Axel Hoos, MD, PhD, SVP Oncology R&D, GSK
Ira Mellman, PhD, VP Cancer Immunology, Genentech
Lindee Goh, Partner, Tapestry Networks
Omid Hamid, MD, Chief, Translational Research and Immunotherapy / Director, Melanoma Therapeutics, The Angeles Clinic
Ramy Ibrahim, MD, VP and Head of R&D, Parker Institute for Cancer Immunotherapy
Moderated by Querida Anderson, Editor in Chief at BioPharm Insight

*This panel is brought to you by BioPharm Insight and The Immuno-Oncology 360° team at The Conference Forum

Networking Reception 6:30 – 8:30 PM

You’re invited to join us for a networking reception following the panel discussion. We know how busy this week is, so feel free to pop-in after the panel for cocktails and light fare. Mix and mingle with the BioPharm Insight team, industry experts and fellow peers.

January 9, 2017

Chandran Art Gallery

San Francisco, CA

Join BioPharm Insight and Intralinks for a panel discussion as key opinion leaders and industry experts take on the tough questions in the field. Topics to be discussed include next-generation I/O therapeutics, pricing and reimbursement expectations, and more.  Following the panel, you’re invited to join us for a networking reception at the Chandran Art Gallery. Sold Out - Click here to be added to the waiting list.

BioPharm Insight is pleased to announce an evening full of expert discussion and networking on January 9th at the Chandran Art Gallery. Complete the form on the right if you’re interested in attending our panel discussion and/or networking reception. Approved attendees will receive a confirmation email.

Panel Discussion 5:30 – 6:30 PM
Immuno-Oncology: Filtering the hype for the next wave of targets

Join us for a panel discussion as key opinion leaders (KOLs) and industry experts take on the tough questions in the field. Topics to be discussed include next-generation I/O therapeutics, pricing and reimbursement expectations, and more.